Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 vs Ipilimumab PK Study in Healthy Males
NCT04868760Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI310 in melanoma and colorectal cancer (CRC) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Area Under the Concentration-time Curve from time zero to infinity at 78 days and Maximum Plasma Concentration at 78 days. Started May 2021; status: completed.
02
Drugs
IBI310
03
Conditions
melanomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04868760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04868760.